Hormone Replacement Therapy Market By Therapy Type (Human Growth Hormone (HGH) Replacement Therapy, Testosterone Replacement Therapy, Thyroid Replacement Therapy, Estrogen Replacement Therapy), By Application (Growth Hormone Deficiency, Menopause, Hypothyroidism, Male Hypogonadism, and Others), By Route of Administration (Oral, Parenteral, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and By Region - Trends, Analysis and Forecast till 2030

Report Code: PMI12319 | Publish Date: April 2024 | No. of Pages: 180

Global Hormone Replacement Therapy Market Companies

  • Merck KgaA
  • Abbott Laboratories
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer Inc.
  • Bayer AG
  • QuatRx Pharmaceuticals
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Amgen, Inc.
  • Novo Nordisk A/S.

Recent News:

  • In February 2023, the Korean Ministry of Food and Drug Safety approved Pfizer's NGENLA to treat growth hormone deficiency.
  • In November 2021, I-MAB Biopharma Co., Ltd. partnered with Jumpcan Pharmaceutical Group to develop and commercialize eftansomatropin alfa (TJ101) in China. TJ101 is a long-acting recombinant human growth hormone currently in Phase 3 clinical trials for the treatment of growth hormone deficiency in children.
  • In August 2020, the US FDA approved Sogroya (somapacitan-beco), an HGH replacement therapy product developed by Novo Nordisk A/S. This product is injected subcutaneously once weekly in adults diagnosed with growth hormone deficiency.